A5088294442- Neurological disorders and treatments
- Parkinson's Disease Mechanisms and Treatments
- Neuroscience and Neural Engineering
- Genetic Neurodegenerative Diseases
- Botulinum Toxin and Related Neurological Disorders
- Pluripotent Stem Cells Research
- CNS Lymphoma Diagnosis and Treatment
- Biomedical Ethics and Regulation
- Moyamoya disease diagnosis and treatment
- Tissue Engineering and Regenerative Medicine
- Systemic Sclerosis and Related Diseases
- Brain Metastases and Treatment
- Pain Management and Treatment
- Pharmacological Effects and Toxicity Studies
- Nerve injury and regeneration
- Neurological Complications and Syndromes
- Bone and Joint Diseases
- Mesenchymal stem cell research
Skåne University Hospital
2016-2023
Lund University
2005-2021
Neuronano (Sweden)
2021
Scania (Sweden)
2013-2015
Centre for Movement Disorders
2014
International Neuromodulation Society
2013
Cell replacement therapies for Parkinson's disease (PD) based on transplantation of pluripotent stem cell-derived dopaminergic neurons are now entering clinical trials. Here, we present quality, safety, and efficacy data supporting the first-in-human STEM-PD phase I/IIa trial along with design. The product was manufactured under GMP quality tested in vitro vivo to meet regulatory requirements. Importantly, no adverse effects were observed upon testing a 39-week rat GLP safety study toxicity,...
The accuracy and precision of frameless neuronavigation as compared to conventional frame-based stereotaxy for implantation deep brain stimulation (DBS) electrodes were studied in 14 patients with essential tremor. DBS implanted bilaterally the ventrolateral thalamus [ventrointermediate nucleus (VIM)] one procedure. Frameless was used on side technique other. Targeting guided by MRI CT imaging. Intraoperative stereotactic plain X-ray verified final electrode positions deviations from planned...
BACKGROUND. Recombinant human PDGF-BB (rhPDGF-BB) reduces Parkinsonian symptoms and increases dopamine transporter (DAT) binding in several animal models of Parkinson's disease (PD). Effects rhPDGF-BB are the result proliferation ventricular wall progenitor cells reversed by blocking mitosis. Based on these restorative effects, we assessed safety tolerability intracerebroventricular (i.c.v.) administration individuals with PD. METHODS. We conducted a double-blind, randomized,...
Abstract Background Cerebral dopamine neurotrophic factor (CDNF) is an unconventional that protects neurons and improves motor function in animal models of Parkinson's disease (PD). Objective The primary objectives this study were to assess the safety tolerability both CDNF drug delivery system (DDS) patients with PD moderate severity. Methods We assessed monthly intraputamenal infusions using investigational DDS, a bone‐anchored transcutaneous port connected four catheters. This phase 1...
<i>Background:</i> Intracerebral infections after deep brain stimulation (DBS) are rare. The published material is limited to 2 case reports. A review of 20 publications 3,818 patients focusing on complications DBS did not reveal one single case. For that reason, we decided present our own experience 4 with this complication. <i>Objectives:</i> To analyze and regarding intracerebral DBS. <i>Methods:</i> Four infection were retrospectively analyzed....
We describe a 23-year-old male patient who presented with spontaneous intermittent and increasing attacks of severe, left-sided thunderclap headache combined rapidly progressive muscle weakness dysphasia, including gradual loss consciousness. Subsequent CT, MRI DSA showed brain ischaemia oedema within the left cerebral hemisphere strict ipsilateral segmental arterial vasoconstriction. Despite extensive medical care, steroids, deteriorated rapidly. However, clinical course changed...
Deep Brain Stimulation (DBS) is an established treatment for motor symptoms in Parkinson's disease (PD). However, side effects often limit the usefulness of treatment.To mitigate this problem, we developed a novel cluster ultrathin platinum-iridium microelectrodes (n = 16) embedded needle shaped gelatin vehicle. In rodent PD-model (6-OHDA unilateral lesion), clusters were implanted subthalamic area up to 8 weeks. open field setting, combinations yielding therapeutic identified using...
Abstract Asymmetry of striatal dopaminergic deficits and motor symptoms is a typical characteristic idiopathic Parkinson’s disease (PD). This study aims to characterise the trend asymmetry in moderate-stage PD. We performed 19-month longitudinal 27 patients with PET-CT imaging appropriate clinical assessments. 11 C-PE2I non-displaceable binding potential (BP ND ) was calculated bilaterally for striatum at baseline follow-up estimate vivo density dopamine transporters (DAT). Changes BP over...